Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO.
Department of Plastic Surgery, MD Anderson Cancer Center, Houston, TX; and.
Blood. 2018 Nov 1;132(18):1889-1898. doi: 10.1182/blood-2018-03-785972. Epub 2018 Sep 12.
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.
乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）是一种新近描述的 T 细胞非霍奇金淋巴瘤，现已被世界卫生组织淋巴肿瘤分类正式认可。该疾病最常表现为乳房植入物周围延迟出现的血清肿，几乎仅发生于有纹理表面的乳房植入物，表现为乳房疼痛、肿胀或不对称、包膜挛缩，但也可表现为乳房肿块和淋巴结受累。与许多其他系统性 T 细胞淋巴瘤亚型相比，BIA-ALCL 的预后较好；然而，与其他非霍奇金淋巴瘤不同，对于局限性疾病，完整的手术切除是这些患者治疗的重要组成部分。在本文中，我们根据美国国家综合癌症网络的共识指南，分享了我们对多学科团队在 BIA-ALCL 的诊断、评估和治疗方面的建议。
